FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294770511> ?p ?o ?g. }

• W4294770511 endingPage "395" @default.
• W4294770511 startingPage "389" @default.
• W4294770511 abstract "Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs). The coronavirus disease 2019 (COVID-19) is associated with increased amounts of pro-inflammatory cytokines, which may affect the outcome of irAEs. Data are limited regarding the impact of COVID-19 on irAEs in ICI-treated cancer patients. Hence, in this study, we retrospectively analyzed ICI-treated adult patients with malignant solid tumors at a single institution between August 2020 and August 2021. Patients who had the most recent ICI treatment over 1-month before or after the positive COVID-19 test were excluded from the study. For the COVID-19 positive group, only the irAEs that developed after COVID-19 infection were considered as events. A total of 579 patients were included in our study, with 46 (7.9%) in the COVID-19 positive group and 533 (92.1%) in the COVID-19 negative group. The baseline characteristics of patients in the 2 groups were similar. With a median follow-up of 331 days (range: 21–2226), we noticed a nonsignificant higher incidence of all-grade irAEs in the COVID-19 positive group (30.4% vs. 19.9%, P =0.18). The incidence of grade 3 and 4 irAEs was significantly higher in the COVID-19 positive group (10.9% vs. 3.2%, P =0.02). Multivariate analysis confirmed the association between COVID-19 infection and increased risk of severe irAE development (odds ratio: 1.08, 95% confidence interval: 1.02–1.14, P =0.01). Our study suggested that COVID-19 may pose a risk of severe irAEs in cancer patients receiving ICIs. Close monitoring and possibly delaying ICI administration could be considered when cancer patients are infected with COVID-19." @default.
• W4294770511 created "2022-09-06" @default.
• W4294770511 creator A5036693256 @default.
• W4294770511 creator A5038397878 @default.
• W4294770511 creator A5040010155 @default.
• W4294770511 creator A5041138991 @default.
• W4294770511 creator A5046884442 @default.
• W4294770511 creator A5049553879 @default.
• W4294770511 creator A5052579493 @default.
• W4294770511 creator A5078629724 @default.
• W4294770511 creator A5080130325 @default.
• W4294770511 creator A5081889727 @default.
• W4294770511 creator A5086051653 @default.
• W4294770511 creator A5090068456 @default.
• W4294770511 date "2022-09-05" @default.
• W4294770511 modified "2023-09-29" @default.
• W4294770511 title "A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors" @default.
• W4294770511 cites W2508205285 @default.
• W4294770511 cites W2508623887 @default.
• W4294770511 cites W2522337762 @default.
• W4294770511 cites W2620163654 @default.
• W4294770511 cites W2744857567 @default.
• W4294770511 cites W2754721894 @default.
• W4294770511 cites W2783137027 @default.
• W4294770511 cites W2889758875 @default.
• W4294770511 cites W2893321040 @default.
• W4294770511 cites W2979167002 @default.
• W4294770511 cites W3011508332 @default.
• W4294770511 cites W3013894953 @default.
• W4294770511 cites W3024506939 @default.
• W4294770511 cites W3033409819 @default.
• W4294770511 cites W3038114343 @default.
• W4294770511 cites W3108518804 @default.
• W4294770511 cites W3108655509 @default.
• W4294770511 cites W3119448318 @default.
• W4294770511 cites W3120038138 @default.
• W4294770511 cites W3128769407 @default.
• W4294770511 cites W3129222772 @default.
• W4294770511 cites W3155810765 @default.
• W4294770511 cites W3173714375 @default.
• W4294770511 doi "https://doi.org/10.1097/cji.0000000000000440" @default.
• W4294770511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36066505" @default.
• W4294770511 hasPublicationYear "2022" @default.
• W4294770511 type Work @default.
• W4294770511 citedByCount "3" @default.
• W4294770511 countsByYear W42947705112023 @default.
• W4294770511 crossrefType "journal-article" @default.
• W4294770511 hasAuthorship W4294770511A5036693256 @default.
• W4294770511 hasAuthorship W4294770511A5038397878 @default.
• W4294770511 hasAuthorship W4294770511A5040010155 @default.
• W4294770511 hasAuthorship W4294770511A5041138991 @default.
• W4294770511 hasAuthorship W4294770511A5046884442 @default.
• W4294770511 hasAuthorship W4294770511A5049553879 @default.
• W4294770511 hasAuthorship W4294770511A5052579493 @default.
• W4294770511 hasAuthorship W4294770511A5078629724 @default.
• W4294770511 hasAuthorship W4294770511A5080130325 @default.
• W4294770511 hasAuthorship W4294770511A5081889727 @default.
• W4294770511 hasAuthorship W4294770511A5086051653 @default.
• W4294770511 hasAuthorship W4294770511A5090068456 @default.
• W4294770511 hasBestOaLocation W42947705111 @default.
• W4294770511 hasConcept C120665830 @default.
• W4294770511 hasConcept C121332964 @default.
• W4294770511 hasConcept C121608353 @default.
• W4294770511 hasConcept C126322002 @default.
• W4294770511 hasConcept C156957248 @default.
• W4294770511 hasConcept C167135981 @default.
• W4294770511 hasConcept C197934379 @default.
• W4294770511 hasConcept C203014093 @default.
• W4294770511 hasConcept C2779134260 @default.
• W4294770511 hasConcept C2780073493 @default.
• W4294770511 hasConcept C3008058167 @default.
• W4294770511 hasConcept C44249647 @default.
• W4294770511 hasConcept C524204448 @default.
• W4294770511 hasConcept C61511704 @default.
• W4294770511 hasConcept C71924100 @default.
• W4294770511 hasConcept C8891405 @default.
• W4294770511 hasConcept C90924648 @default.
• W4294770511 hasConceptScore W4294770511C120665830 @default.
• W4294770511 hasConceptScore W4294770511C121332964 @default.
• W4294770511 hasConceptScore W4294770511C121608353 @default.
• W4294770511 hasConceptScore W4294770511C126322002 @default.
• W4294770511 hasConceptScore W4294770511C156957248 @default.
• W4294770511 hasConceptScore W4294770511C167135981 @default.
• W4294770511 hasConceptScore W4294770511C197934379 @default.
• W4294770511 hasConceptScore W4294770511C203014093 @default.
• W4294770511 hasConceptScore W4294770511C2779134260 @default.
• W4294770511 hasConceptScore W4294770511C2780073493 @default.
• W4294770511 hasConceptScore W4294770511C3008058167 @default.
• W4294770511 hasConceptScore W4294770511C44249647 @default.
• W4294770511 hasConceptScore W4294770511C524204448 @default.
• W4294770511 hasConceptScore W4294770511C61511704 @default.
• W4294770511 hasConceptScore W4294770511C71924100 @default.
• W4294770511 hasConceptScore W4294770511C8891405 @default.
• W4294770511 hasConceptScore W4294770511C90924648 @default.
• W4294770511 hasIssue "9" @default.
• W4294770511 hasLocation W42947705111 @default.
• W4294770511 hasLocation W42947705112 @default.
• W4294770511 hasLocation W42947705113 @default.

• next